Phase 2 study of Carboplatin / Nab-paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion

Trial Profile

Phase 2 study of Carboplatin / Nab-paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jun 2016 Planned End Date changed from 31 Jul 2017 to 31 Mar 2019.
    • 17 Apr 2014 Status changed from planning to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 17 Apr 2014 Planned End Date changed to 31 Jul 2017 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top